» Articles » PMID: 34064918

Radiomics Analysis of 3D Dose Distributions to Predict Toxicity of Radiotherapy for Cervical Cancer

Overview
Journal J Pers Med
Date 2021 Jun 2
PMID 34064918
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Standard treatment for locally advanced cervical cancer (LACC) is chemoradiotherapy followed by brachytherapy. Despite radiation therapy advances, the toxicity rate remains significant. In this study, we compared the prediction of toxicity events after radiotherapy for locally advanced cervical cancer (LACC), based on either dose-volume histogram (DVH) parameters or the use of a radiomics approach applied to dose maps at the voxel level. Toxicity scores using the Common Terminology Criteria for Adverse Events (CTCAE v4), spatial dose distributions, and usual clinical predictors for the toxicity of 102 patients treated with chemoradiotherapy followed by brachytherapy for LACC were used in this study. In addition to usual DVH parameters, 91 radiomic features were extracted from rectum, bladder and vaginal 3D dose distributions, after discretization into a fixed bin width of 1 Gy. They were evaluated for predictive modelling of rectal, genitourinary (GU) and vaginal toxicities (grade ≥ 2). Logistic Normal Tissue Complication Probability (NTCP) models were derived using clinical parameters only or combinations of clinical, DVH and radiomics. For rectal acute/late toxicities, the area under the curve (AUC) using clinical parameters was 0.53/0.65, which increased to 0.66/0.63, and 0.76/0.87, with the addition of DVH or radiomics parameters, respectively. For GU acute/late toxicities, the AUC increased from 0.55/0.56 (clinical only) to 0.84/0.90 (+DVH) and 0.83/0.96 (clinical + DVH + radiomics). For vaginal acute/late toxicities, the AUC increased from 0.51/0.57 (clinical only) to 0.58/0.72 (+DVH) and 0.82/0.89 (clinical + DVH + radiomics). The predictive performance of NTCP models based on radiomics features was higher than the commonly used clinical and DVH parameters. Dosimetric radiomics analysis is a promising tool for NTCP modelling in radiotherapy.

Citing Articles

Predicting grade II-IV bone marrow suppression in patients with cervical cancer based on radiomics and dosiomics.

Tang Y, Pang Y, Tang J, Sun X, Wang P, Li J Front Oncol. 2024; 14:1493926.

PMID: 39669364 PMC: 11634748. DOI: 10.3389/fonc.2024.1493926.


Acute hematologic toxicity prediction using dosimetric and radiomics features in patients with cervical cancer: does the treatment regimen matter?.

Yue H, Li X, You J, Feng P, Du Y, Wang R Front Oncol. 2024; 14:1365897.

PMID: 38835389 PMC: 11148289. DOI: 10.3389/fonc.2024.1365897.


Contouring of emerging organs-at-risk (OARS) of the female pelvis and interobserver variability: A study by the Italian association of radiotherapy and clinical oncology (AIRO).

Augurio A, Macchia G, Caravatta L, Lucarelli M, Di Gugliemo F, Vinciguerra A Clin Transl Radiat Oncol. 2023; 43:100688.

PMID: 37854671 PMC: 10579954. DOI: 10.1016/j.ctro.2023.100688.


Feature Importance Analysis of a Deep Learning Model for Predicting Late Bladder Toxicity Occurrence in Uterine Cervical Cancer Patients.

Cheon W, Han M, Jeong S, Oh E, Lee S, Lee S Cancers (Basel). 2023; 15(13).

PMID: 37444573 PMC: 10340146. DOI: 10.3390/cancers15133463.


Association of Multi-Phasic MR-Based Radiomic and Dosimetric Features with Treatment Response in Unresectable Hepatocellular Carcinoma Patients following Novel Sequential TACE-SBRT-Immunotherapy.

Ho L, Lam S, Zhang J, Chiang C, Chan A, Cai J Cancers (Basel). 2023; 15(4).

PMID: 36831445 PMC: 9954441. DOI: 10.3390/cancers15041105.


References
1.
Swamidas J, Kirisits C, De Brabandere M, Hellebust T, Siebert F, Tanderup K . Image registration, contour propagation and dose accumulation of external beam and brachytherapy in gynecological radiotherapy. Radiother Oncol. 2019; 143:1-11. DOI: 10.1016/j.radonc.2019.08.023. View

2.
Bentzen S, Constine L, Deasy J, Eisbruch A, Jackson A, Marks L . Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010; 76(3 Suppl):S3-9. PMC: 3431964. DOI: 10.1016/j.ijrobp.2009.09.040. View

3.
Ribeiro I, Janssen H, De Brabandere M, Nulens A, De Bal D, Vergote I . Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients. Radiother Oncol. 2016; 120(3):447-454. DOI: 10.1016/j.radonc.2016.04.016. View

4.
Kirchheiner K, Potter R, Tanderup K, Lindegaard J, Haie-Meder C, Petric P . Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study. Int J Radiat Oncol Biol Phys. 2016; 94(5):1088-98. DOI: 10.1016/j.ijrobp.2015.12.363. View

5.
Moran A, Daly M, Yip S, Yamamoto T . Radiomics-based Assessment of Radiation-induced Lung Injury After Stereotactic Body Radiotherapy. Clin Lung Cancer. 2017; 18(6):e425-e431. DOI: 10.1016/j.cllc.2017.05.014. View